Conference Track

Lung Cancer

Source: CCO Independent Conference Coverage of the 2009 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Pemetrexed Maintenance Therapy Significantly Improves PFS and OS in Advanced Nonsquamous NSCLC
SATURN: Significantly Improved PFS With Erlotinib Maintenance Therapy vs Placebo in EGFR-Positive Patients With Advanced NSCLC
ATLAS: Improved PFS With Addition of Erlotinib to Bevacizumab Maintenance Therapy After First-line Chemotherapy in Patients With Advanced NSCLC
Vandetanib Added to Standard Chemotherapy Significantly Improves PFS in Patients With Recurrent NSCLC
HDAC Inhibitor Vorinostat Significantly Improves Tumor Response When Added to Chemotherapy for Frontline NSCLC Treatment
EGFR Mutation Status Predicts Clinical Benefit of Gefitinib vs Carboplatin/Paclitaxel in First-line NSCLC Treatment
Benefit From Addition of Cetuximab to Chemotherapy Associated With Rash; Survival Improved in NSCLC Regardless of KRAS Status or EGFR Copy Number
ZEST and ZEAL: Phase III Trials of Vandetanib in Advanced-Stage NSCLC After Previous Treatment Failure
First-line Paclitaxel, Carboplatin, Cetuximab, Bevacizumab Followed by Maintenance Cetuximab, Bevacizumab Safe and Active in Advanced NSCLC

Expert Analysis

Expert Analysis: Lung Cancer

Faculty:

Barbara J. Gitlitz, MD
David R. Gandara, MD
Ramaswamy Govindan, MD

Corey J. Langer, MD, FACP

Learning Objectives

Upon completion of this activity, participants should be able to:

Analyze data from recent studies regarding current standards of care for lung cancer
Evaluate new data on novel agents and therapeutic approaches for lung cancer
Employ the integration of new agents and treatment strategies into the clinical management of patients with lung cancer
Evaluate the role of molecular biomarkers in the treatment of patients with lung cancer

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: August 04, 2009

Expiration Date: August 03, 2010

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing contact hours

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.